Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy Study of Cenobamate in Pediatric Subjects With Partial-onset Seizures
NCT05067634Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Jan 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of cenobamate in partial epilepsy, sponsored by SK Life Science, Inc.. Started Jan 2022; status: completed.
02
Drugs
cenobamate
03
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT05067634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067634.